Strides Pharma UK Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Strides Pharma UK Limited Pharmaceutical Import Records from India — 5 Products, $5.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Strides Pharma UK Limited — Pharmaceutical Importer Profile (2026) | 5 Products, $5.4M Trade | TransData Nexus

Strides Pharma UK Limited

Pharmaceutical Importer · United Kingdom · Antimalarial & Antiparasitic Focus · $5.4M Total Trade · DGFT Verified

Strides Pharma UK Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $5.4M across 5 products in 5 therapeutic categories. Based on 150 verified import shipments from Indian Customs (DGFT) records, Strides Pharma UK Limited is the #1 buyer in 1 product including Quinine. Strides Pharma UK Limited sources from 7 verified Indian suppliers, with Strides Pharma Science Limited accounting for 92.9% of imports.

Strides Pharma UK Limited — Import Portfolio & Supplier Network

Strides Pharma UK Limited import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Strides Pharma UK Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Strides Pharma Science Limited	$6.9M	217	92.9%
Bafna Pharmaceuticals Limited	$200.0K	4	2.7%
Naari Pharma Private Limited	$92.8K	2

What Formulations Does Strides Pharma UK Limited Import?

Formulation	Value	Ships
Macrogol plus electrolytes [13.72g][sachets][powder for oral solution] po	$234.1K	5
Naproxen tablets 500MG	$200.0K	4
Colecalciferol 800 IU capsules [soft	$150.0K	3
Prednisolone tablets BP [5MG] [spuk] 335282.00x	$133.8K	3
Prednisolone tablets BP [5MG] [spuk] 333182.00x	$133.3K	3
Prednisolone tablets BP [5MG] [spuk] 327162.00x	$131.8K	3
Metformin hydrochloride prolonged release tablets 1000MG (73260x 4 x 14s	$128.4K	3
Indapamide tablets [2.5MG] [sc]	$104.0K	3
Buspirone hydrochloride	$100.0K	2
Vancomycin hydrochloride capsules [125MG	$100.0K	2
Strivit-d3 colecalciferol 3200 IU capsules [soft gelatin] 15764.00 x	$100.0K	2
Quinine bisulfate tablets BP [300MG] [fc] [co-pharma] 33758.00 x	$100.0K	2
Metformin hydrochloride prolonged release tablets 500MG (72454x 4 x 14s)	$100.0K	2
Baclofen tablets 10MG 51010.00x	$93.7K	2
Quinine sulfate tablets BP 300MG (fc). (53834 x 2 x 14s	$88.9K	3

Strides Pharma UK Limited imports 162 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Quinine	Antimalarial & Antiparasitic	$2.4M	47	8.8%	1
2	Prednisolone	Respiratory	$2.0M	48	1.1%	16
3	Loperamide	Gastrointestinal	$727.6K	39	1.0%	6
4	Omega	Nutritional Supplements	$200.0K	4	1.1%	6
5	Warfarin	Cardiovascular	$170.9K	12	2.3%	10

Strides Pharma UK Limited imports 5 pharmaceutical products across 5 categories into United Kingdom totaling $5.4M. The company is the #1 buyer for 1 product: Quinine.

Strides Pharma UK Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Strides Pharma UK Limited, established in 1993 and headquartered in Watford, Hertfordshire, is a subsidiary of Strides Pharma Science Limited, a global pharmaceutical company operating in over 100 countries. The company specializes in the licensing, marketing, and supply of generic and over-the-counter (OTC) medicines within the United Kingdom. Strides Pharma UK Limited is committed to delivering high-quality, cost-effective pharmaceutical products, emphasizing patient care and safety.

The company's operations are supported by a robust global supply network, including its own active pharmaceutical ingredient (API) production and four overseas manufacturing sites approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This infrastructure enables Strides Pharma UK Limited to maintain consistent stock levels, typically holding at least six months in advance, ensuring uninterrupted availability of its products.

2Distribution Network

Strides Pharma UK Limited's distribution network is centralized at its headquarters in Watford, Hertfordshire. The company operates from the Metro Centre facility, which is fully approved by the MHRA and adheres to Good Manufacturing Practice (GMP) standards. This facility serves as the primary hub for the company's operations, including warehousing, logistics, and distribution activities.

While specific details about additional warehouse locations or logistics capabilities beyond the Watford facility are not publicly disclosed, Strides Pharma UK Limited's strategic partnerships and global supply chain infrastructure suggest a capacity to serve the UK market effectively. The company's focus on maintaining a reliable supply chain, supported by its own API production and MHRA-approved manufacturing sites, underscores its commitment to ensuring consistent product availability across the United Kingdom.

3Industry Role

Strides Pharma UK Limited operates as a pharmaceutical importer and distributor within the United Kingdom's pharmaceutical supply chain. The company focuses on licensing, marketing, and supplying generic and OTC medicines, positioning itself as a key player in the wholesale distribution segment. By leveraging its global manufacturing capabilities and regulatory expertise, Strides Pharma UK Limited ensures the availability of a diverse portfolio of pharmaceutical products to meet the needs of the UK healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Strides Pharma UK Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Strides Pharma UK Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, Strides Pharma Science Limited. This supplier accounts for approximately 92.9% of the total import value, indicating a strong dependency on this source. Such concentration can present risks, including potential supply chain disruptions if issues arise with the primary supplier.

However, the company's sourcing strategy also reflects a strategic choice to maintain consistency in product quality and supply reliability. The substantial volume of imports from Strides Pharma Science Limited suggests a well-established and stable relationship, likely characterized by favorable terms and mutual trust. The presence of additional suppliers, such as Bafna Pharmaceuticals Limited and Naari Pharma Private Limited, provides a degree of diversification, mitigating some risks associated with single-source dependency.

2Supply Chain Resilience

Strides Pharma UK Limited's supply chain resilience is bolstered by its ownership of active pharmaceutical ingredient (API) production facilities and partnerships with multiple manufacturing sites. The company operates four overseas manufacturing sites approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), ensuring compliance with stringent regulatory standards.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing the safety, efficacy, and quality of medicines and medical devices. The MHRA operates under the Department of Health and Social Care, ensuring that pharmaceutical products meet the required standards before they are marketed in the UK.

Key legislation governing pharmaceutical imports into the UK includes the Human Medicines Regulations 2012, which implement European Union directives related to medicinal products. This legislation outlines the requirements for marketing authorizations, manufacturing, and distribution of medicines. The MHRA is responsible for granting marketing authorizations, conducting inspections, and enforcing compliance with these regulations. (gov.uk)

2Import Licensing & GMP

To import human medicines into the United Kingdom, companies must obtain a Wholesale Distribution Licence (WDA(H)) from the MHRA. This license authorizes the holder to import, store, and distribute medicines within the UK. Additionally, a Marketing Authorisation (MA) is required for each medicinal product, ensuring that the product has been evaluated and approved for safety, efficacy, and quality. (gov.uk)

Good Manufacturing Practice (GMP) certification is essential for manufacturers supplying medicines to the UK market. The MHRA recognizes GMP certificates from various regulatory bodies, including the European Union, the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Manufacturers must ensure compliance with these standards to maintain product quality and regulatory approval. (gov.uk)

Strides Pharma UK Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Strides Pharma UK Limited's product strategy focuses on three core areas: branded generics, generics, and OTC products. This diversified approach allows the company to cater to a broad spectrum of patient needs and market demands. The emphasis on branded generics enables Strides Pharma UK Limited to offer cost-effective alternatives to branded medicines, providing patients with affordable treatment options without compromising on quality.

The company's focus on generics and OTC products aligns with the growing demand for affordable healthcare solutions in the UK. By leveraging its global manufacturing capabilities and regulatory expertise, Strides Pharma UK Limited ensures the availability of a diverse portfolio of pharmaceutical products, contributing to the sustainability and accessibility of the UK's healthcare system.

2Sourcing Profile

Strides Pharma UK Limited's sourcing strategy is characterized by a strong reliance on its parent company, Strides Pharma Science Limited, for the supply of active pharmaceutical ingredients (APIs) and finished pharmaceutical formulations. This approach ensures consistency in product quality and supply reliability. The company's focus on maintaining a robust supply chain, supported by its own API production and MHRA-approved manufacturing sites, underscores its commitment to delivering high-quality pharmaceutical products to the UK market.

Market Positioning

Frequently Asked Questions — Strides Pharma UK Limited

What products does Strides Pharma UK Limited import from India?

Strides Pharma UK Limited imports 5 pharmaceutical products across 5 categories. Top imports: Quinine ($2.4M), Prednisolone ($2.0M), Loperamide ($727.6K), Omega ($200.0K), Warfarin ($170.9K).

Who supplies pharmaceuticals to Strides Pharma UK Limited from India?

Strides Pharma UK Limited sources from 7 verified Indian suppliers. The primary supplier is Strides Pharma Science Limited (92.9% of imports, $6.9M).

What is Strides Pharma UK Limited's total pharmaceutical import value?

Strides Pharma UK Limited's total pharmaceutical import value from India is $5.4M, based on 150 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Strides Pharma UK Limited focus on?

Strides Pharma UK Limited imports across 5 categories. The largest: Antimalarial & Antiparasitic (43.4%), Respiratory (36.3%), Gastrointestinal (13.4%).

Get Full Strides Pharma UK Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.